Immix Biopharma Q3 EPS Forecast Reduced by HC Wainwright

Immix Biopharma, Inc. (NASDAQ:IMMX) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Immix Biopharma in a note issued to investors on Monday, August 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.17) for the quarter, down from their prior forecast of ($0.14). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.01) EPS and Q4 2027 earnings at $0.31 EPS.

Other analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Friday, July 17th. Needham & Company LLC began coverage on shares of Immix Biopharma in a research report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 price target on the stock. Lifesci Capital started coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 price target for the company. Citigroup assumed coverage on shares of Immix Biopharma in a research report on Thursday, June 18th. They set a “buy” rating for the company. Finally, Bank of America assumed coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.29.

Immix Biopharma Price Performance

Shares of IMMX opened at $11.49 on Wednesday. The business’s fifty day moving average price is $9.46 and its 200 day moving average price is $8.94. Immix Biopharma has a 12-month low of $1.94 and a 12-month high of $12.14. The stock has a market capitalization of $625.17 million, a PE ratio of -13.06 and a beta of 0.11.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01).

Institutional Investors Weigh In On Immix Biopharma

Several large investors have recently added to or reduced their stakes in IMMX. Vanguard Group Inc. boosted its holdings in shares of Immix Biopharma by 4.5% during the third quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after acquiring an additional 31,625 shares during the period. Tocqueville Asset Management L.P. increased its holdings in shares of Immix Biopharma by 37.4% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after acquiring an additional 10,950 shares during the period. Imprint Wealth LLC acquired a new stake in shares of Immix Biopharma in the 3rd quarter worth about $141,000. Citadel Advisors LLC bought a new stake in Immix Biopharma in the 3rd quarter valued at about $188,000. Finally, Susquehanna International Group LLP lifted its position in Immix Biopharma by 78.8% in the 3rd quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock valued at $190,000 after purchasing an additional 40,032 shares during the last quarter. 11.26% of the stock is owned by institutional investors and hedge funds.

More Immix Biopharma News

Here are the key news stories impacting Immix Biopharma this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $25.00 price target, implying substantial upside from recent trading levels. The analyst expects Immix Biopharma to reach positive earnings of $0.31 per share in the fourth quarter of 2027, suggesting a potential longer-term path toward profitability.
• Positive Sentiment: A separate report cited a consensus analyst target price of $20.71, which is also above the company’s recent share price. Immix Biopharma, Inc. Receives $20.71 Consensus Target Price from Analysts
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day short-interest ratio. Because the data appears inconsistent—including a reported “NaN” percentage change—it provides little reliable insight into current trading pressure.
• Negative Sentiment: HC Wainwright reduced its estimates for third-quarter 2026 EPS to a loss of $0.17 from a loss of $0.14, fourth-quarter 2026 EPS to a loss of $0.19 from a loss of $0.15, and full-year 2026 EPS to a loss of $0.72 from a loss of $0.62. The revisions indicate weaker expected results and continued losses in the near term.
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Immix Biopharma investors. The notice does not establish wrongdoing, but news of a potential securities-related investigation can weigh on investor sentiment and increase legal uncertainty. Pomerantz Law Firm Investor Alert

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.